Founded in 2022, San Francisco-based Weave Bio offers an end-to-end, AI-driven regulatory platform that helps pharmaceutical companies, biotech firms, CROs, and consultants create, manage, and submit complex regulatory dossiers. The software integrates AI across data extraction, authoring, review, publishing, and health-authority response workflows, cutting regulatory timelines by more than 50% while improving consistency and compliance. Initially adopted for pre-clinical IND filings, the platform now supports clinical, approval-stage, and post-market submissions and complies with FDA, EMA, and other global standards. Recent recognition includes winning the "Biotech AI Innovation of the Year" award. Future product plans include full coverage of NDA/BLA filings, deeper AI analytics for portfolio insights, and geographic expansion into Europe, Japan, and Latin America. The company will also grow its commercial team to reinforce market leadership. With the new Series A financing, Weave Bio’s total funding reaches $36 million, providing resources for accelerated product development and global scale-up.

Total raised

$30M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2025